Future Devices of Venous Interventions
|
|
- Vernon Hamilton
- 5 years ago
- Views:
Transcription
1 Future Devices of Venous Interventions Director of Peripheral Vascular Medicine Department of Shin Kong Wu Ho-Su Memorial Hospital, Taiwan Interventional Cardiologist Tien-Yu Wu MD
2 Disclosure Speaker name:... I have the following potential conflicts of interest to report: Consulting Employment in industry Stockholder of a healthcare company Owner of a healthcare company Other(s) I do not have any potential conflict of interest
3 Increased Awareness CDC Thrombophilia pilot sites APHA-CDC leadership conference NQF/Joint Commissions, and CMS policies NIH funding DVT and venous disease Surgeon General Call to Action SVS/AVF DVT Guidelines AHA PTS Guidelines AHRQ: VTE #1 prevention opportunity US Senate declares March DVT awareness month ASH Surveillance Workshop ATTRACT Trial AHA DVT Guidelines CIRSE Stent Guidelines CDC Thrombosis and Hemostasis Centers Research and Prevention Network established; CDC & NATT promote awareness Beckman M, et al. Am J Prev Med Vedantham S, et al. Rationale Am Heart J Jaff MR, et al. Circulation Kahn SR, et al. Circulation Meissner H, et al. J Vasc Surg 2012 Mahnken AH, et al. Cardiovasc Intervent Radiol. 2014
4 Current Venous Intevention Acute or chronic deep vein thrombosis CDT or PMT PTA with stenting May-Thurner Syndrome Iliac vein stenting placed an important role to restore and maintain venous out flow
5 PCDT Did not prevent the development of PTS Significant higher rate of major bleeding within 10 days (1.7% vs 0.3%; P =.049) Reduce early DVT symptoms as well as PTS severity
6 In the past decades Only Wall stent and arterial Nitinol stent available Wall stent Better radial force Foreshortening Migration Arterial Nitinol stent Weak radial force Not large enough No stents design for Vein
7 May-Thurner Syndrome Wall stent Nitinol stent
8 Wall stent vs Nitinol stent
9 Wall stent vs Nitinol stent
10 Artery Nitinol Stent
11 Anatomy
12
13 What is a workman without his tools?
14 Ideal Venous Stent Design Large diameters design Easy and accurate deployment Easy to deploy Radiopaque Limited foreshortening Long lengths Balance between radial force and flexibility High radial force High compression resistance High flexibility
15 VENOVO Venous Stent BARD Next Generation Venous stent
16 VENOVO Venous Stent Self expanding nitinol Flexible, fine tubular mesh prosthesis Outward radial force established vessel patency Ends flared 3mm to ensure adequate wall apposition
17 VENOVO Venous Stent 3 radiopaque tantalum markers 6 nitinol connectors 3 nitinol connectors 3 non-radiopaque nitinol markers
18 VENOVO Venous Stent Delivery System Tri-axial system 0.035, over-the-wire Safety lock slider Dual speed thumbwheel Large thumbwheel for slow deployment Small thumbwheel for fast deployment
19 Stent Lengths VENOVO Venous Stent System 40 mm 60 mm 80 mm 100 mm 120 mm 140 mm 160 mm Stent Diameters 10 mm 12 mm 14 mm 16 mm 18 mm 20 mm 8F 9F 10F
20 Radial Force and Crush Resistance
21 BARD N= 20 Optimed Sinus Venous N=3 Cook Zilver Vena N -3 Stent Flexibility
22 Visibility Ovine Model, AP View Post stent deployment Ovine Model, AP View Compressed stent prior to deployment Ovine Model, AP View During stent deployment
23 VERNACULAR Trial The BARD VENOVO Venous Stent Study - A Prospective, Non- Randomized, Multi-Center, Single-Arm Study of the Treatment of Iliofemoral Occlusive Disease an Assessment for Effectiveness and Safety Design: Prospective, multi-center, non-randomized, single-arm Core lab & DSMB Purpose: to assess the safety and effectiveness of the VENOVO Venous Stent for the treatment of iliofemoral occlusive disease including Acute or Chronic Deep Vein Thrombosis (DVT), May- Thurner Syndrome, or any combination of the above. Investigative Sites: 35 sites in the US, Europe, and Australia/NZ Subjects: 170 subjects
24 Key Inclusion/Exclusion Inclusion Unilateral disease of common femoral, common/external iliac Symptomatic venous outflow obstruction > 50% by venography CEAP >3 or VCSS >2 RVD 7 mm - 19 mm Exclusion Contralateral disease and lesions that extend into IVC or below lesser trochanter Uncorrectable bleeding diathesis or active coagulopathy Previous venous stents Can t cross occlusion
25 VERNACULAR Trial Primary endpoints: Primary patency (12 months) Freedom from MACE (30 days) Evaluated against literature derived performance goals Key secondary endpoints: VCSS/ CEAP/ QoL assessment Procedure/technical success Freedom from TVR/TLR Primary patency at 24 and 36 mo. Stent fracture The result is still pending
26 IVUS Guide Iliac Vein Stenting ( , 22 + months mean follow-up) Procedure successful rate 100 % Tien-Yu Wu et al. paper submitted
27 Numbers of Stent Occlusion Tien-Yu Wu et al. paper submitted
28 Primary Patency Patency = Duplex study + free from clinical symptom Tien-Yu Wu et al. paper submitted
29 Risk factor vs stent occlusion Tien-Yu Wu et al. paper submitted
30 Symptom improvement Average CEAP reduction: 2.66 Tien-Yu Wu et al. paper submitted
31 Conclusion From the literature and my study, iliac vein stenting has be proved to be safe and effective in treating certain iliac vein disease. The venous system is quite different from artery. It shouldn t be treated in the same way (stent). We need more adequate design of the devices for venous system. We hope the venovo venous stent could give us a promising result in the near future.
32 Thank You!
33 Future Devices of Venous Interventions Director of Peripheral Vascular Medicine Department of Shin Kong Wu Ho-Su Memorial Hospital, Taiwan Interventional Cardiologist Tien-Yu Wu MD
VERNACULAR Trial & Clinical Experience with the VENOVO Venous Stent
Stephen Black, MD VERNACULAR Trial & Clinical Experience with the VENOVO Venous Stent 1 Speaker Disclaimers The speakers presentation today is on behalf of Bard Peripheral Vascular, Inc. Any discussion
More informationVIRTUS: Trial Design and Primary Endpoint Results
VIRTUS: Trial Design and Primary Endpoint Results Mahmood K. Razavi, MD St. Joseph Cardiac and Vascular Center Orange, CA, USA IMPORTANT INFORMATION: These materials are intended to describe common clinical
More informationClinical results of venous stents. Michael K. W. Lichtenberg MD, FESC
Clinical results of venous stents Michael K. W. Lichtenberg MD, FESC Conflict of Interest - Disclosure Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement or affiliation
More informationVENOVO Venous Stent Update on the Vernacular Trial
VENOVO Venous Stent Update on the Vernacular Trial Dr. Sunder Narasimhan, MBBS, MS Senior Consultant Vascular and Endovascular Surgeon Apollo Hospital, Bangalore, India VENOVO is a registered trademark
More informationThe Ideal Venous Stent and Early Results from Venous Stent Trials PNEC, Seattle
The Ideal Venous Stent and Early Results from Venous Stent Trials 2017 PNEC, Seattle Bill Marston MD Professor, Div of Vascular Surgery University of N. Carolina DISCLOSURES William Marston, MD Consultant/Advisory
More informationVIVO-EU Results: Prospective European Study of the Zilver Vena TM Venous Stent in the Treatment of Symptomatic Iliofemoral Venous Outflow Obstruction
VIVO-EU Results: Prospective European Study of the Zilver Vena TM Venous Stent in the Treatment of Symptomatic Iliofemoral Venous Outflow Obstruction Gerard J O Sullivan, M.D. and Jennifer McCann-Brown,
More informationComplex ilio-caval revascularization in chronic venous obstruction with the Venovo Stent. Michael K. W. Lichtenberg MD, FESC
Complex ilio-caval revascularization in chronic venous obstruction with the Venovo Stent Michael K. W. Lichtenberg MD, FESC German Venous Center Arnsberg, Germany Not available for sale or distribution
More informationREKANALISATION CHRONISCH VENÖSER VERSCHLÜSSE. Michael K. W. Lichtenberg, FESC
REKANALISATION CHRONISCH VENÖSER VERSCHLÜSSE Michael K. W. Lichtenberg, FESC Conflict of Interest - Disclosure Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement
More informationThe evidence for venous interventions is evolving- many patients do actually benefit. Nils Kucher University Hospital Bern Switzerland
The evidence for venous interventions is evolving- many patients do actually benefit Nils Kucher University Hospital Bern Switzerland Disclosure Speaker name: Nils Kucher X X I have the following potential
More informationShould We Be More Aggressive in the Treatment of Acute DVT?
DISCLOSURES Consultant Penumbra, Inc. UCSF Vascular Surgery Symposium April 6, 2017 K. Pallav Kolli, MD Assistant Professor of Clinical Radiology University of California, San Francisco 17 yo male, DVT
More informationVenous stent experience in Arnsberg Michael K. W. Lichtenberg MD, FESC
Venous stent experience in Arnsberg Michael K. W. Lichtenberg MD, FESC IMPORTANT INFORMATION: These materials are intended to describe common clinical considerations and procedural steps for the on-label
More informationHow to best approach chronic venous occlusions?
How to best approach chronic venous occlusions? Prof. Nils Kucher Director Venous Thromboembolism Reseach Group University Hospital Bern nilskucher.com Disclosure Speaker name: Nils Kucher X X I have the
More informationPatency rates and clinical results of the Veniti VICI Stent for treatment of iliac vein lesion Data from the Arnsberg Venous Registry
Patency rates and clinical results of the Veniti VICI Stent for treatment of iliac vein lesion Data from the Arnsberg Venous Registry Michael K. W. Lichtenberg MD, FESC Conflict of Interest - Disclosure
More informationA Dedicated Venous Self-expanding Oblique Hybrid Nitinol Stent (Sinus-Obliquus Stent)
A Dedicated Venous Self-expanding Oblique Hybrid Nitinol Stent (Sinus-Obliquus Stent) Anna Stuck, Rolf P. Engelberger, Nils Kucher Division of Angiology Cantonal Hospital Fribourg & Bern University Hospital
More informationVIRTUS Trial: Pivotal Cohort 12-Month Primary Safety and Efficacy Results of the VICI Venous Stent System
VIRTUS Trial: Pivotal Cohort 12-Month Primary Safety and Efficacy Results of the VICI Venous Stent System Mahmood K. Razavi, MD St. Joseph Cardiac and Vascular Center Orange, CA, USA Disclosure Speaker
More informationChronic Iliocaval Venous Occlusive Disease
none Chronic Iliocaval Venous Occlusive Disease David Rigberg, M.D. Clinical Professor of Surgery Division of Vascular Surgery University of California Los Angeles Chronic Venous Occlusive Disease Chronic
More informationImage-Guided Approach to Treatment of Patients with Nonthrombotic
Image-Guided Approach to Treatment of Patients with Nonthrombotic May Thurner Syndrome Brian DeRubertis, MD, FACS Associate Professor of Surgery Division of Vascular Surgery UCLA School of Medicine Los
More informationIntervention for Deep Venous Thrombosis and Pulmonary Embolus
Intervention for Deep Venous Thrombosis and Pulmonary Embolus Michael R. Jaff, DO Paul and Phyllis Fireman Endowed Chair in Vascular Medicine Massachusetts General Hospital Professor of Medicine Harvard
More informationAnticoagulation therapy following endovascular treatment of iliofemoral deep vein thrombosis
Anticoagulation therapy following endovascular treatment of iliofemoral deep vein thrombosis Tim Sebastian, M.D. University Hospital Zurich Clinic for Angiology Disclosure Speaker name: Tim Sebastian I
More informationTechniques for thrombus removal in acute DVT Benefits of an Endovascular Approach for Rapid Flow Restoration in DVT
Techniques for thrombus removal in acute DVT Benefits of an Endovascular Approach for Rapid Flow Restoration in DVT Michael K. W. Lichtenberg, MD, FESC Vascular Centre Arnsberg, Germany Disclosure Speaker
More informationCOVERA covered stent to treat stenosis in arteriovenous fistula: 6-month results from the prospective, multi-center, randomized AVeNEW study
COVERA covered stent to treat stenosis in arteriovenous fistula: 6-month results from the prospective, multi-center, randomized AVeNEW study Panagiotis Kitrou MD, MSc, PhD, EBIR Consultant Interventional
More informationComplex Iliocaval Reconstruction PNEC. Seattle WA. Bill Marston MD Professor, Div of Vascular Surgery University of N.
Complex Iliocaval Reconstruction 2017 PNEC. Seattle WA Bill Marston MD Professor, Div of Vascular Surgery University of N. Carolina DISCLOSURES William Marston, MD Consultant/Advisory Board: Veniti, Cardinal
More informationAspirex for Upper and Lower Extremity DVT
Aspirex for Upper and Lower Extremity DVT Steven Kum MD Vascular & Endovascular Surgeon Director of Vascular Service Changi General Hospital Singapore Disclosure Speaker name:... I have the following potential
More informationWhat Really Matters to Patient is QOL: Veniti Virtus Venous Feasibility Trial
DISCLOSURES Speaker name: Lowell S. Kabnick, MD, FACS... I have the following potential conflicts of interest: Consultant and shareholder, VENITI, Inc. Consultant to BARD What Really Matters to Patient
More informationUnderstanding of the importance of venous
The Critical Need for an Iliofemoral Venous Obstruction Classification System An overview of a potential classification system to better identify and treat iliofemoral venous outflow obstruction. BY WILLIAM
More informationProven Performance Through Innovative Design *
Proven Performance Through Innovative Design * Deliver Our Next Generation AV Covered Stent Results The COVERA Vascular Covered Stent builds upon proven technologies from the category leader in AV Access.
More informationTreatment of Chronic DVT with EKOS: Reproducing ACCESS PTS Data in Every Day Clinical Practice
Treatment of Chronic DVT with EKOS: Reproducing ACCESS PTS Data in Every Day Clinical Practice Mert Dumantepe, MD Acibadem Altunizade Hospital, Istanbul, Turkey Department of Cardiovascular Surgery Disclosure
More informationComplete Evaluation of the Chronic Venous Patient: Recognizing deep venous obstruction. Erin H. Murphy, MD Rane Center
Complete Evaluation of the Chronic Venous Patient: Recognizing deep venous obstruction Erin H. Murphy, MD Rane Center Disclosure Speaker name: Erin H. Murphy... I have the following potential conflicts
More informationChristian Wissgott MD, PhD Assistant Director, Radiology Westküstenkliniken Heide
2-Year Results Of The Tack Optimized Balloon Angioplasty (TOBA) Trial For Fem- Pop Lesions Demonstrates Safety and Efficacy Of The Tack Endovascular System In Repairing Focal Post-PTA Dissections Christian
More informationImaging, it s central role in planning and guiding intervention. Prof. Luis Izquierdo. MD, PhD, FEBVS
Imaging, it s central role in planning and guiding intervention Prof. Luis Izquierdo. MD, PhD, FEBVS IMPORTANT INFORMATION: These materials are intended to describe common clinical considerations and procedural
More informationChronic deep venous occlusions: Case planning, recanalization and stent technique
Chronic deep venous occlusions: Case planning, recanalization and stent technique Michael K. W. Lichtenberg, FESC German Venous Center Arnsberg, Germany Conflict of Interest - Disclosure Within the past
More informationImproved clinical outcomes Evidence on venous thrombectomy followed by stenting
Improved clinical outcomes Evidence on venous thrombectomy followed by stenting Michael K. W. Lichtenberg, MD, FESC Vascular Centre Arnsberg, Germany Venous Centre Arnsberg, Germany Disclosure Speaker
More informationThe Role of Lithotripsy in Solving the Challenges of Vascular Calcium. Thomas Zeller, MD
The Role of Lithotripsy in Solving the Challenges of Vascular Calcium Thomas Zeller, MD 1 1 Disclosure Speaker name: Thomas Zeller... I have the following potential conflicts of interest to report: X X
More informationBalloon Expandable Covered Stents. Suddenly a Crowded Space
Novel Balloon Expandable Covered Stents for Aorto-iliac Occlusive Disease: New Trial Data makes for an Interesting Balloon Expandable Covered Stents Comparison in Aorto-iliac Occlusive Disease: Andrew
More informationImproved clinical outcomes Evidence on venous mechanical thrombectomy followed by stenting
Improved clinical outcomes Evidence on venous mechanical thrombectomy followed by stenting Michael K. W. Lichtenberg, MD, FESC Vascular Centre Arnsberg, Germany German Venous Centre Arnsberg, Germany Disclosure
More informationOn Which Criteria Do You Select Your Stent for Ilio-femoral Venous Obstruction? North American Point of View
On Which Criteria Do You Select Your Stent for Ilio-femoral Venous Obstruction? North American Point of View Peter Gloviczki, MD Ying Huang, MD, PhD Division of Vascular and Endovascular Surgery, Mayo
More information- Our patients with iliofemoral DVT - Effective thrombus removal with purely mechanical thrombectomy can lead to better outcomes
- Our patients with iliofemoral DVT - Effective thrombus removal with purely mechanical thrombectomy can lead to better outcomes Michael K. W. Lichtenberg, FESC Conflict of Interest - Disclosure Within
More informationStarting with deep venous treatment
Starting with deep venous treatment Carsten Arnoldussen, MD Interventional Radiologist Maastricht University Medical Centre, Maastricht VieCuri Medical Centre, Venlo The Netherlands Background Maastricht
More informationCopy Here. The Easy One.. What is the Role of Thrombus Removal in Acute Proximal DVT after ATTRACT? Deep Venous Thrombosis Spectrum
What is the Role of Thrombus Removal in Acute Proximal DVT after ATTRACT? Mitchell J. Silver DO FACC FSVM RPVI Director, Center for Critical Limb Care Riverside Methodist Hospital Ohio Health Heart and
More informationIliofemoral DVT: Miminizing Post-Thrombotic Syndrome
Iliofemoral DVT: Miminizing Post-Thrombotic Syndrome Catherine K. Chang, MD FACS Vascular Surgery San Diego Southern California Permanente Medical Group Acute Deep Venous Thrombosis Incidence & Outcomes
More informationEndovascular treatment of severe TASC C and D external iliac artery occlusive disease. SAINT-LEBES Bertrand Toulouse FRANCE
Endovascular treatment of severe TASC C and D external iliac artery occlusive disease SAINT-LEBES Bertrand Toulouse FRANCE Disclosure Speaker name: SAINT-LEBES I have the following potential conflicts
More informationVenous Stents Placed Below the Inguinal Ligament: No Worries
Venous Stents Placed Below the Inguinal Ligament: No Worries Disclosure Speaker name: Lowell S. Kabnick, MD, FACS, FACPh, RPhS... I have the following potential conflicts of interest to report: Consulting:
More informationTreatment Strategies for Long Lesions of greater than 20 cm
Treatment Strategies for Long Lesions of greater than 20 cm Donald L. Jacobs, MD C. Rollins Hanlon Professor and Chair Chair of the Department of Surgery Saint Louis University Disclosure Speaker name:
More informationUltrasound-assisted catheter-directed thrombolysis: Does it really work? The BERNUTIFUL trial
Ultrasound-assisted catheter-directed thrombolysis: Does it really work? The BERNUTIFUL trial Rolf P. Engelberger Division of Angiology CHUV, Lausanne & Inselspital, Bern Switzerland Disclosure Speaker
More informationStraub Endovascular System &
Straub Endovascular System & S t r a u b E n d o v a s c u l a r To o l s Straub Endovascular System Effective debulking in occluded arteries and veins Effective debulking in many indications Rotarex
More informationSuccessful recanalisation of venous thrombotic occlusions with Aspirex mechanical thrombectomy. Michael K. W. Lichtenberg
Successful recanalisation of venous thrombotic occlusions with Aspirex mechanical thrombectomy Michael K. W. Lichtenberg Disclosure Speaker name: Michael Lichtenberg... I have the following potential conflicts
More informationAcute Safety and Technical Results of the EverFlex Self-Expanding Stent with New Delivery System (ENTRUST)
Acute Safety and Technical Results of the EverFlex Self-Expanding Stent with New Delivery System (ENTRUST) Carl Wahlgren, MD/PhD Department of Vascular Surgery, Karolinska University Hospital/Karolinska
More informationUpdate on Tack Optimized Balloon Angioplasty (TOBA) Below the Knee. Marianne Brodmann, MD Medical University Graz Graz, Austria
Update on Tack Optimized Balloon Angioplasty (TOBA) Below the Knee Marianne Brodmann, MD Medical University Graz Graz, Austria Critical Limb Ischemia Infrapopliteal arterial disease is a leading source
More informationComplications of endovascular treatment of May-Thurner syndrome George Geroulakos
Complications of endovascular treatment of May-Thurner syndrome George Geroulakos Professor of Vascular Surgery, National and Kapodistrian University of Athens Director, Department of Vascular Surgery,
More informationCHALLENGES IN FEMORO-POPLITEAL STENTING
CHALLENGES IN FEMORO-POPLITEAL STENTING Karathanos C MD, MSc, PhD, Athanasoulas A, Rousas N, Spanos K, Giannoukas A Department of Vascular Surgery, University Hospital of Larissa, Faculty of Medicine,
More informationVenous interventions in DVT
Venous interventions in DVT Sriram Narayanan Chief of Vascular and Endovascular Surgery, Tan Tock Seng Hospital A/Prof of Surgery, National University of Singapore ANTI-COAGULATION LMWH Warfarin x 6m Acute
More informationPATIENTS WITH CLI THE THREE YEARS OUTCOME OF ENDOLUMINAL BYPASS FOR PATIENTS WITH CLI
JORGE FERNÁNDEZ NOYA ANGIOLOGY AND VASCULAR SURGERY DEPARTMENT UNIVERSITARY CLINICAL HOSPITAL SANTIAGO DE COMPOSTELA THE THREE YEARS OUTCOME OF ENDOLUMINAL BYPASS FOR Disclosure Speaker name: Jorge Fernández
More informationThe ZILVERPASS study a randomized study comparing ZILVER PTX stenting with Bypass in femoropopliteal lesions Preliminary report
The ZILVERPASS study a randomized study comparing ZILVER PTX stenting with Bypass in femoropopliteal lesions Preliminary report G. Biro, M. Bosiers on behalf of ZILVERPASS Study Group Disclosure Speaker
More informationMicromesh technology in carotid artery treatment what is next? Max Amor MD Clinique Louis Pasteur, Essey-Les-Nancy France
Micromesh technology in carotid artery treatment what is next? Max Amor MD Clinique Louis Pasteur, Essey-Les-Nancy France www.incathlab.com Disclosure Speaker name: Max Amor, MD.... I have the following
More informationThe Conservative and Active Management of Post Thrombotic Syndrome
The Conservative and Active Management of Post Thrombotic Syndrome Stephen Black Consultant Vascular Surgeon Clinical Lead for Venous and Lymphoedema Surgery Guys and St Thomas Hospital London How important
More informationGORE EXCLUDER AAA Endoprosthesis demonstrates long-term durability. Michel Reijnen Rijnstate Hospital Arnhem, The Netherlands
GORE EXCLUDER AAA Endoprosthesis demonstrates long-term durability Michel Reijnen Rijnstate Hospital Arnhem, The Netherlands Disclosure Speaker name: Michel Reijnen I have the following potential conflicts
More informationBC Vascular Day. Contents. November 3, Abdominal Aortic Aneurysm 2 3. Peripheral Arterial Disease 4 6. Deep Venous Thrombosis 7 8
BC Vascular Day Contents Abdominal Aortic Aneurysm 2 3 November 3, 2018 Peripheral Arterial Disease 4 6 Deep Venous Thrombosis 7 8 Abdominal Aortic Aneurysm Conservative Management Risk factor modification
More informationPercutaneous Mechanical Thrombectomy for Acute Iliofemoral DVT with the Aspirex Catheter: The Dijon Experience
JFICV 2018, Beaune Percutaneous Mechanical Thrombectomy for Acute Iliofemoral DVT with the Aspirex Catheter: The Dijon Experience Prof. Romaric LOFFROY, MD, PhD, FCIRSE Chief, Department of Vascular and
More informationThe Evidence Base for Treating Acute DVT
The Evidence Base for Treating Acute DVT Mr Chung Sim Lim Consultant Vascular Surgeon and Honorary Lecturer Royal Free London NHS Foundation Trust and University College London NIHR UCLH Biomedical Research
More informationMR and CT venography for imaging venous obstruction
MR and CT venography for imaging venous obstruction Hendrik von Tengg-Kobligk University Hospitals Inselspital Bern Hendrik.vonTengg@insel.ch Disclosure Speaker name:...hendrik von Tengg-Kobligk... I have
More informationPulsar stent technology
Pulsar stent technology Michael K. W. Lichtenberg Vascular Center Arnsberg Disclosures Speaker name: Michael Lichtenberg... I have the following potential conflicts of interest to report: X Consulting
More informationIVUS is strongly recommanded before treating a venous femoro-iliac obstruction CONS. F Thony CHU Grenoble
IVUS is strongly recommanded before treating a venous femoro-iliac obstruction CONS F Thony CHU Grenoble Disclosure Speaker name: Frédéric THONY I do not have any potential conflict of interest Introduction
More informationHybrid Procedures for Peripheral Obstructive Disease - Step by Step -
Hybrid Procedures for Peripheral Obstructive Disease - Step by Step - Holger Staab, MD University Hospital Leipzig, Germany Clinic for Vascular Surgery Disclosure Speaker name:..holger Staab... I have
More informationSustained Release. Superior Results.
ELUVIA Drug-Eluting Vascular Stent System Sustained Release. Superior Results. Superiority determined in Post Hoc Superiority Analysis. 12-Month Primary Patency rate of 86.8% in the Eluvia arm (n=309)
More information5-YEAR SUPERIOR RESULTS. Compared to PTA and Zilver BMS 1. NOW WITH 140 mm LENGTH STENTS
SUPERIOR 5-YEAR RESULTS Compared to PTA and Zilver BMS 1 NOW WITH 140 mm LENGTH STENTS 1. Dake MD, Ansel GM, Jaff MR, et al. Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal
More informationAccess More Patients. Customize Each Seal.
Access More. Customize Each Seal. The Least Invasive Path Towards Proven Patency ULTRA LOW PROFILE TO EASE ADVANCEMENT The flexible, ultra-low 12F ID Ovation ix delivery system enables you to navigate
More informationWhen Outcomes Matter, Design Matters
to receive our latest news and key activities. Cordis S.M.A.R.T. Self-Expanding Nitinol Lower Extremity Solutions When Outcomes Matter, Design Matters For superficial femoral artery (SFA) and iliac lesions.
More informationPreliminary 6-month results of VMI-CFA trial
Preliminary 6-month results of VMI-CFA trial Koen Deloose, MD Head Vascular Surgery, AZ Sint Blasius, Dendermonde, Belgium Disclosure slide Speaker name: Koen Deloose, MD I have the following potential
More informationThe ZILVERPASS study a randomized study comparing ZILVER PTX stenting with Bypass in femoropopliteal lesions
The ZILVERPASS study a randomized study comparing ZILVER PTX stenting with Bypass in femoropopliteal lesions Dr. Sven Bräunlich Department of Angiology University-Hospital Leipzig, Germany Disclosure Speaker
More informationArch Repair with the Bolton Medical RelayBranch Thoracic Stent-graft system: Multicenter experience
Arch Repair with the Bolton Medical RelayBranch Thoracic Stent-graft system: Multicenter experience Joost van Herwaarden, MD, PhD University Medical Center, Utrecht Disclosure I have the following potential
More informationPharmaco-mechanical techniques stand alone procedures? Peter Neglén, MD, PhD SP Vascular Center Limassol Cyprus
Pharmaco-mechanical techniques stand alone procedures? Peter Neglén, MD, PhD SP Vascular Center Limassol Cyprus Faculty Disclosure Peter Neglén, M.D., Ph.D Stockholder/Founder of Veniti, Inc. Member, Medical
More informationZilver PTX Post-Market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan: 24-Month Results
Post-Market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan: 24-Month Results Hiroyoshi Yokoi, MD, Fukuoka Sannou Hospital Fukuoka, Japan On behalf
More informationStep by step Hybrid procedures in peripheral obstructive disease. Holger Staab, MD University Hospital Leipzig, Germany Clinic for Vascular Surgery
Step by step Hybrid procedures in peripheral obstructive disease Holger Staab, MD University Hospital Leipzig, Germany Clinic for Vascular Surgery Disclosure Speaker name: H.H. Staab I have the following
More informationInterventions for AV-Shunt stenosis: What works best PTA, Stent or DCB?
Interventions for AV-Shunt stenosis: What works best PTA, Stent or DCB? Martin Forlee Vascular Surgeon Cape Town Disclosure Speaker name: Martin Forlee I have the following potential conflicts of interest
More informationVenous stenting in Marseille
Venous stenting in Marseille Olivier HARTUNG, MD, MSc CHU Nord, Marseille, FRANCE Disclosure Speaker name: Olivier HARTUNG I have the following potential conflicts of interest to report: x Consulting :
More informationKoen Keirse, MD RZ Tienen, Belgium
Clinical Benefits of the Vanguard IEP Peripheral Balloon Angioplasty System with Integrated Embolic Protection from the ENTRAP Study Koen Keirse, MD RZ Tienen, Belgium Disclosure Speaker name: Koen Keirse...
More informationLutonix AV Clinical Trial
Long Term Effects of LUTONIX 035 DCB Catheter Interim 24 Month Results Ta-Wei Su MD Vascular surgery CGMH Taiwan Disclosure I have the following potential conflicts of interest to report: Consulting Employment
More informationExpanding to every demand: The GORE VIABAHN VBX Stent Graft
Expanding to every demand: The GORE VIABAHN VBX Stent Graft GORE, VIABAHN, and designs are trademarks of W. L. Gore & Associates. 2017 W. L. Gore & Associates, Inc. Program Faculty Martin Austermann, MD
More informationTHERE IS NO ROLE FOR SURGICAL THERAPY FOR DVT
THERE IS NO ROLE FOR SURGICAL THERAPY FOR DVT Tara D. Balint, MD FACS Sentara RMH Thursday, June 14, 2018 1 Objectives of treatment for DVT Prevent death from PE Prevent recurrent VTE Prevent post-thrombotic
More informationFinally, the Control You Need to Deliver Accurate Treatment
Finally, the Control You Need to Deliver Accurate Treatment LIFESTREAM Covered Stent. has joined BD When you reach for a balloon expandable stent, you require accuracy. The LIFESTREAM Balloon Expandable
More informationCase Study of Implantation of a VICI VENOUS STENT - Combined NIVL and PTS Stenting
Case Study of Implantation of a VICI VENOUS STENT - Combined NIVL and PTS Stenting Courtesy of Mr. Stephen Black United kingdom Patient History 25 y/o female 2011: Conservatively treated ilio-femoral DVT
More informationDurability of The Endurant Stent-Graft through 5 Years
Durability of The Endurant Stent-Graft through 5 Years Michel S. Makaroun MD Co-Director, UPMC Heart and Vascular Institute Professor and Chair, Division of Vascular Surgery University of Pittsburgh School
More informationHow to perform CFA Supera deployment. Koen Deloose, MD Head Dept Vascular Surgery AZ Sint Blasius Dendermonde, Belgium
How to perform CFA Supera deployment Koen Deloose, MD Head Dept Vascular Surgery AZ Sint Blasius Dendermonde, Belgium Disclosure slide Speaker name: Koen Deloose, MD I have the following potential conflicts
More informationLow profile TEVAR: is it an added value? Michel Bosiers, G. Torsello Münster
Low profile TEVAR: is it an added value? Michel Bosiers, G. Torsello Münster Disclosure Speaker name:...michel Bosiers... I have the following potential conflicts of interest to report: Consulting Employment
More informationMinimizing Burden, the effect of thin strut and low Chronic Outward Force SE stents
Minimizing Burden, the effect of thin strut and low Chronic Outward Force SE stents Prof. Yong LIU The affiliated hospital of southwest medical university LINC AP 2018, Hong Kong 13-15 th March Disclosure
More informationPatient assessment and strategy making for endovenous treatment
Patient assessment and strategy making for endovenous treatment Raghu Kolluri, MD Director Vascular Medicine OhioHealth Riverside Methodist Hospital Columbus, OH Disclosures Current Medtronic Consultant/
More informationVenogram Versus Intravascular Ultrasound for Diagnosing and Treating Iliofemoral Vein Obstruction (VIDIO)
Venogram Versus Intravascular Ultrasound for Diagnosing and Treating Iliofemoral Vein Obstruction (VIDIO) Report From a Multicenter, Prospective Study of Iliofemoral Vein Interventions Paul J. Gagne, MD,
More informationUpdate in femoral angioplasty & stenting PRO
MEET 2008 Update in femoral angioplasty & stenting Will extra-long stents be a solution for SFA disease? PRO Patrick Peeters, MD Chief department Cardiovascular & Thoracic Surgery, Imelda Hospital, Bonheiden,
More informationWhich Stent Is Best for Various Femoropopliteal Anatomy? 2018 Pacific Northwest Endovascular Conference June 15-26, 2018 Seattle, WA
Which Stent Is Best for Various Femoropopliteal Anatomy? 2018 Pacific Northwest Endovascular Conference June 15-26, 2018 Seattle, WA Brian DeRubertis, MD, FACS Associate Professor of Surgery UCLA Division
More informationThe Supera stent In retrograde vascular access for SFA ostium treatment: The SUPRA-FAST Registry
The Supera stent In retrograde vascular access for SFA ostium treatment: PESTRICHELLA VINCENZO MD Chief Endovascular cathlab Mater Dei Hospital BARI- Italy Disclosure Speaker name:...pestrichella VINCENZO...
More informationThe BATTLE Trial Comparing Bare Metal to Drug Eluting Stents for Intermediate Length Lesions of the SFA
The BATTLE Trial Comparing Bare Metal to Drug Eluting Stents for Intermediate Length Lesions of the SFA BATTLE RCT investigators: Y. Gouëffic, A. Sauguet, P. Desgranges, P. Feugier, E. Rosset, E. Ducasse,
More informationEndovascular treatment of acquired arteriovenous fistula with severe hemodynamic effects: a case report
Endovascular treatment of acquired arteriovenous fistula with severe hemodynamic effects: a case report The Leipzig Interventional Course, January 24 27, 2017 El Samman K., Šedivý P., Šnajdrová A., Přindišová
More informationEarly Clinical Results with the Valiant Mona LSA Branch Stent-Graft
Early Clinical Results with the Valiant Mona LSA Branch Stent-Graft Frank R. Arko III, MD Professor of Cardiovascular Surgery Director, Endovascular Surgery Co-Director, Aortic Institute Carolinas Medical
More informationUpdate on the OPTIMIZE BTK Trial. Marianne Brodmann, MD Division of Angiology Medical University Graz, Austria
Update on the OPTIMIZE BTK Trial Marianne Brodmann, MD Division of Angiology Medical University Graz, Austria Disclosure Speaker name: Marianne Brodmann, MD... I have the following potential conflicts
More informationWhat is the optimal time window for treating deep venous thrombosis? Acute vs subacute vs chronic
What is the optimal time window for treating deep venous thrombosis? Acute vs subacute vs chronic Peter A. Schneider, MD Chief of Vascular Therapy Kaiser Foundation Hospital Honolulu, Hawaii Disclosure
More informationLessons learnt from DES in the SFA is there any ideal concept so far?
Wednesday, January 25, 2017 - Time: 11:49-11:55 DEEP DIVE SESSION: Lower limb interventions (part II) Lessons learnt from DES in the SFA is there any ideal concept so far? S.Müller-Hülsbeck, MD, EBIR,
More informationOptimal Utilization of Thrombolytics
April 8-9, 2011 New York LaGuardia Marriott COMPLETE MANAGEMENT OF VENOUS DISEASE Optimal Utilization of Thrombolytics Anthony J. Comerota, MD, FACS, FACC Director, Jobst Vascular Institute Adjunct Professor
More informationVariation of stent placement for distal abdominal aorta Lesion
Variation of stent placement for distal abdominal aorta Lesion Tatsuki Doijiri M.D Department of Cardiology Yamato-Seiwa Hospital Kanagawa Japan Disclosure Speaker name: Tatsuki Doijiri... I have the following
More informationManagement of In-stent Restenosis after Lower Extremity Endovascular Procedures
Management of In-stent Restenosis after Lower Extremity Endovascular Procedures Piotr Sobieszczyk, MD Associate Director, Cardiac Catheterization Laboratory Cardiovascular Division and Vascular Medicine
More information